Image pharmaphorum Editor Views & Analysis What can pharma marketing learn from other regulated industr... The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. Views & Analysis Emotional empathy is driving brand equity How the COVID-19 pandemic is forging pharmaceutical brands into better shape. Press releases Partner Content Survey finds quality control is a major challenge in clinica... Many respondents experience frequent problems and blame human error Wokingham, United Kingdom — 6 August 2020 Views & Analysis Bad behaviour: why understanding human behaviour can improve... Why did I do that? A common question I often ask myself after opening the biscuit packet for the third time in an hour. Load more results
Views & Analysis What can pharma marketing learn from other regulated industr... The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers.
Views & Analysis Emotional empathy is driving brand equity How the COVID-19 pandemic is forging pharmaceutical brands into better shape.
Press releases Partner Content Survey finds quality control is a major challenge in clinica... Many respondents experience frequent problems and blame human error Wokingham, United Kingdom — 6 August 2020
Views & Analysis Bad behaviour: why understanding human behaviour can improve... Why did I do that? A common question I often ask myself after opening the biscuit packet for the third time in an hour.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
